You just read:

Health Canada issues notice of compliance for Gilead's Harvoni™ (ledipasvir/sofosbuvir), the first once-daily single tablet regimen for the treatment of genotype 1 chronic hepatitis C

News provided by

Gilead Sciences, Inc.

Oct 16, 2014, 14:44 ET